IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, announced a new contract for the installation of a Proteus ONE[1] proton therapy solution with Proton International Arkansas LLC – a joint venture formed by Proton International, the University of Arkansas for Medical Sciences (UAMS), Baptist Health, and Arkansas Children’s.

January 3, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, announced a new contract for the installation of a Proteus ONE[1] proton therapy solution with Proton International Arkansas LLC – a joint venture formed by Proton International, the University of Arkansas for Medical Sciences (UAMS), Baptist Health, and Arkansas Children’s.

The solution will be installed in the three-story Radiation Oncology Center, which is under construction and part of the UAMS Winthrop P. Rockefeller Cancer Institute. The Proteus ONE system will be equipped with Pencil Beam Scanning (PBS), Cone Beam Computed Tomography (CBCT), hand pendant for easy patient positioning and a fully integrated quality assurance (QA) hardware and software package from IBA Dosimetry America, Inc. The contract includes a long-term operation and maintenance agreement to be provided by IBA, with Proton International LLC expecting to start treating patients by 2023.

The typical end-user price for a Proteus ONE system with a 10-year maintenance contract usually ranges between $40-50 million. IBA has received the first payment and will start recognizing revenue in 2021.

Olivier Legrain, Chief Executive Officer of IBA, commented: "We are pleased to sign this new contract with Proton International Arkansas LLC, bringing accelerated access to proton therapy to cancer patients in Arkansas. The US is of key strategic importance for our business and this latest contract reinforces our leading position in this market, being our 7th Proteus ONE system and 19th proton therapy system sold in the country overall. We look forward to supporting the University of Arkansas for Medical Sciences, Baptist Health, and Arkansas Children’s in their mission of bringing this much needed technology to the state and are pleased to welcome them to IBA Campus[2], the largest community of proton therapy experts."

"UAMS is excited to be partnering with IBA and to be bringing this advanced technology to patients in Arkansas, making it easier for those in need to access this highly effective treatment," said UAMS Chancellor Cam Patterson, M.D., MBA. "This is part of our continued commitment to improving the health and well-being of all Arkansans."

"This collaboration enables children in Arkansas to gain access to this life-saving therapy close to home," said Marcy Doderer, President and CEO of Arkansas Children’s. "We are proud to work on this exciting initiative that provides the most advanced care and improves quality of life for the children and families we serve."

"Ensuring the best care for patients and responding to the changing health needs of the local community of Arkansas are central to Baptist Health’s mission, a value that is truly reinforced by this partnership and the delivery of such an innovative technology for the treatment of cancer." said Troy Wells, President and Chief Executive Officer of Baptist Health.

Chris Chandler, Chief Executive Officer of Proton International, said, "Following the successful completion of two projects with IBA in Royal Oak, and in the Netherlands, the Proton International team is pleased to be working with our partners in Arkansas to bring this important technology to its citizens and the surrounding region."

For more information: www.iba-worldwide.com

Related Content

News | Nuclear Imaging

January 26, 2022 — On January 24, the Emergency Response Team (ERT) of Nuclear Medicine Europe (NMEu) communicated that ...

Time January 26, 2022
arrow
News | Nuclear Imaging

January 26, 2022 — IBA, a world leader in particle accelerator technology and the leading provider of ...

Time January 26, 2022
arrow
News | Prostate Cancer

January 24, 2022 — New research has confirmed the accuracy of the novel European Association of Urology (EAU) risk ...

Time January 24, 2022
arrow
News | Prostate Cancer

January 19, 2022 — For the first time, researchers led by a team from the UCLA Jonsson Comprehensive Cancer Center used ...

Time January 19, 2022
arrow
News | Lung Imaging

January 17, 2022 — A recent, substantial decline in lung cancer deaths is associated with earlier diagnosis of lung ...

Time January 17, 2022
arrow
News | Radiation Therapy

January 13, 2022 — A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance ...

Time January 13, 2022
arrow
News | Radiation Therapy

January 10, 2022 — Nanobiotix, a late-stage clinical biotechnology company pioneering physics-based approaches to expand ...

Time January 10, 2022
arrow
News | Molecular Imaging

Janaury 10, 2022 — The Department of Energy’s National Nuclear Security Administration (NNSA) and Office of ...

Time January 10, 2022
arrow
News | Radiation Oncology

January 7, 2022 — Varian and parent company Siemens Healthineers have been recognized in the annual IMV ServiceTrak ...

Time January 07, 2022
arrow
News | Radiation Oncology

January 7, 2022 — A Case Western Reserve University-led team of scientists has used Artificial Intelligence (AI) to ...

Time January 07, 2022
arrow
Subscribe Now